We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$450M
AUM Growth
+$20.6M
Cap. Flow
+$27.2M
Cap. Flow %
6.04%
Top 10 Hldgs %
53.49%
Holding
51
New
15
Increased
13
Reduced
3
Closed
15

Top Buys

Rank Stock Value
1
RLMD icon
Relmada Therapeutics
RLMD
+$16M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$15.7M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
4
PASG icon
Passage Bio
PASG
+$12.4M
5
RNAM
Avidity Biosciences
RNAM
+$11.9M

Top Sells

Rank Stock Value
1
KDMN
Kadmon Holdings, Inc.
KDMN
+$29.4M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$16.1M
3
UTHR icon
United Therapeutics
UTHR
+$16M
4
BIIB icon
Biogen
BIIB
+$13.4M
5
SAGE
Sage Therapeutics
SAGE
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.61%
3 Real Estate 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KNSA icon
26
Kiniksa Pharmaceuticals
KNSA
$5.99B
$6.32M 1.4%
536,738
+56,738
+12% +$697K
PVLA
27
Palvella Therapeutics
PVLA
$2.22B
$5.86M 1.3%
+19,375
New +$6.2M
KALV
28
DELISTED
KalVista Pharmaceuticals
KALV
$5.45M 1.21%
+411,937
New +$6.56M
DNTH icon
29
Dianthus Therapeutics
DNTH
$5.83B
$5.18M 1.15%
73,125
– –
PYXS icon
30
Pyxis Oncology
PYXS
$279M
$4.39M 0.97%
+400,000
New +$4.58M
SYRE icon
31
Spyre Therapeutics
SYRE
$8.08B
$4.32M 0.96%
36,410
+410
+1% +$64.7K
NKTR icon
32
CALL
Nektar Therapeutics
NKTR
$2.28B
$2.75M 0.61%
+13,593
New +$2.95M
ABUS icon
33
Arbutus Biopharma
ABUS
$1.01B
$2.6M 0.58%
+668,907
New +$2.6M
CABA icon
34
Cabaletta Bio
CABA
$434M
$1.79M 0.4%
+472,433
New +$5.04M
RFL icon
35
Rafael Holdings
RFL
$107M
$1.46M 0.32%
289,714
– –
PNT
36
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$1.07M 0.24%
+190,520
New +$1.43M
APLS
37
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-200,000
Closed -$6.59M
BIIB icon
38
Biogen
BIIB
$32.2B
– –
-47,500
Closed -$13.4M
COLL icon
39
Collegium Pharmaceutical
COLL
$721M
– –
-121,342
Closed -$2.4M
CTMX icon
40
CytomX Therapeutics
CTMX
$610M
– –
-1,500,000
Closed -$7.63M
FOLD
41
DELISTED
Amicus Therapeutics
FOLD
– –
-249,000
Closed -$2.38M
IFRX icon
42
InflaRx
IFRX
$295M
– –
-551,918
Closed -$1.43M
NKTR icon
43
Nektar Therapeutics
NKTR
$2.28B
– –
-33,646
Closed -$7.3M
OLMA icon
44
Olema Pharmaceuticals
OLMA
$847M
– –
-329,086
Closed -$9.07M
PBYI icon
45
Puma Biotechnology
PBYI
$476M
– –
-1,300,000
Closed -$9.11M
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$654M
– –
-220,863
Closed -$7.09M
RPTX
47
DELISTED
Repare Therapeutics
RPTX
– –
-93,137
Closed -$2.44M
SAGE
48
DELISTED
Sage Therapeutics
SAGE
– –
-269,010
Closed -$11.9M
UTHR icon
49
United Therapeutics
UTHR
$21.6B
– –
-86,667
Closed -$16M
DRNA
50
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-799,999
Closed -$16.1M
1
2
3

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q4 2021 Portfolio in Review

As of Q4 2021, Great Point Partners held 51 positions worth $450M, up 4.8% from $429M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Great Point Partners deployed $27.2M of net new capital in Q4 2021, opening 15 new positions and adding to 13 existing holdings. Its largest new stake was Relmada Therapeutics: 717,320 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $7.21M trimmed.

  • Great Point Partners's largest Q4 2021 buy was Relmada Therapeutics: 717,320 shares worth $16.2M.
  • Great Point Partners added most to Vaxcyte in Q4 2021, an estimated $9.35M increase.
  • Great Point Partners's biggest Q4 2021 reduction was Rocket Pharmaceuticals, cutting an estimated $7.21M.
  • Great Point Partners fully exited Kadmon Holdings, Inc. in Q4 2021, selling an estimated $29.4M.
  • Great Point Partners's ten largest holdings make up 53% of its $450M portfolio in Q4 2021.
  • Great Point Partners opened 15 new positions and closed 15 in Q4 2021.
  • Great Point Partners's portfolio value rose 4.8% quarter-over-quarter to $450M.

Based on Great Point Partners's 13F filing for Q4 2021, filed 14 Feb 2022.